64 results about "Drug specific IgE" patented technology

This invention provides methods for determining drug specificity, therapeutic index and effective doses for individual patients. According to the methods of the invention, graded levels of drug are applied to a biological sample or a patient. A plurality of cellular constituents are measured to determine the activity of the drug on a target pathway and at least one off-target pathway. A drug specificity is determined by comparing the target and off target activities of the drug. A therapeutic concentration (or dose) is defined as a concentration (or dose) of the drug that induces certain response in the target pathway. A toxic concentration (or dose) is defined as a concentration (or dose) of the drug that induces certain response in the off target pathway. Therapeutic index is the ratio of the toxic concentration over therapeutic concentration. Methods are also provided to determine an effective dose of a drug for a patient by measuring the activity of the drug on the particular patient.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.

An astrocyte-specific drug carrier containing a retinoid derivative and / or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

A method for preparing both main label and warning label portions for a container useful in dispensing drugs by a pharmacist in which the main label portion contains specific drug or patient information and the warning label portion contains one or more warnings specific to the drug or patient information includes the steps of providing a backing sheet having the main label portion and the warning label portion releasably adhered thereto, printing the drug or patient information on the warning label during only one printing pass, and then affixing both the main label portion and the warning label portion to a drug container.

An astrocyte-specific drug carrier containing a retinoid derivative and / or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

A transfer needle comprises: a liquid-specific member; and a medicament-specific member to be separably connected or joined to the liquid-specific member in a liquid-tight state. The liquid-specific member comprises: a liquid-specific hollow needle projecting toward the opposite side from the medicament-specific member. The medicament-specific member comprises: a medicament-specific hollow needle projecting toward the opposite side from the liquid-specific member and communicating with the liquid-specific hollow needle. A female lure is provided on at least one of the liquid-specific member and the medicament-specific member at a position opposing to the other. The female lure communicates with the one hollow needle and is separably connected with an injection needle connecting portion of a syringe in a liquid-tight state.

Disclosed is a conjugate comprising a biologically active agent (drug) linked to a subcellular targeting moiety that targets a drug specifically to the nucleus. Targeting is achieved by attaching a steroid hormone (or an analog) to the drug. The steroid hormone attached to the drug binds its corresponding receptor, the formation of the receptor-ligand complex results in the internalization of the complex into the nucleus, thus resulting in nuclear translocation of the drug. Also disclosed is a conjugate (comprising the complex of the drug and the steroid hormone) bound to a polymer by spacers allowing for concurrent passive targeting to the tumor cell (afforded by attachment to the polymer by the EPR effect) and nuclear targeting of the conjugate (due to the presence of the steroid). Using a suitable degradable spacer allows for the release of free drug in the tumor and enhances nuclear targeting efficacy. The polymer can be further linked to a cellular targeting molecule, where the targeting molecule directs the polymer to specific cells. One may thus be able to effectively target drugs to the nucleus of tumor cells. With little or modifications, several therapeutic agents can be targeted using the invention.

The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

A gene-drug specific system for classifying individual genetic variants based on strength-of-evidence of clinical utility from published scientific and clinical data that support their effect on modifying drug response and behavior. This allows categorization of the genetic variants into evidence classes that have a wide range of uses such as pharmacogenomic molecular diagnostics and personalized medicine research designed to guide the clinical implementation of PGx. Furthermore, this information can be combined with a knowledgebase of drug-response phenotypes, a knowlegebase of specific drug-induced outcomes and individual patient diplotype information for a gene-drug combination into a programmed computer to output corresponding patient-specific predicted drug responses.

A device operable in a medication compliance system, wherein a patient has a patient-specific and medication-specific compliance schedule. The device includes a processor and memory; at least one long-range telemetry module, operatively connected to the processor, and providing connectivity between the device and remote networks, the at least one long-range telemetry module including at least one cellular radio; at least one short-range telemetry module, operatively connected to the processor, and providing connectivity between the device and local devices; and a display controlled by the processor, the display providing feedback from the medication compliance system, in accordance with a patient-specific and medication-specific compliance schedule.

Embodiments of the invention include a method of collecting and reporting quality of life data from a patient. A patient may participate in a collection of surveys during the course of disease treatment that are automatically tailored to the patient's disease state using multidimensional tools to generate quality of life metrics. Reports are generated from the aggregate data to aid in treatment of the patient by enhancing patient / healthcare provider communications, patient education and by giving the healthcare provider reports on quality of life metrics correlated to the prescribed treatments, comorbid diseases, disease specific and medication specific review of systems and patient compliance with the prescribed treatments. Further, data from multiple patients are aggregated for reports that can provide evaluations of the effect of prescribed treatments, reasons for patient non-compliance with prescribed treatments and the prevalence and effect of off-label use of medications.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.

The invention relates to a preparation method of a magnetic carbon nanotube surface molecular imprinting material. The preparation method comprises three steps of magnetic carbon nanotube preparation, surface molecular imprinting reaction and template molecule elution. The preparation method has simple processes and can be controlled easily. The magnetic carbon nanotube surface molecular imprinting material obtained by the preparation method has a specific recognition function, excellent magnetic properties, high mechanical strength, a high adsorption capacity and fast binding dynamical properties, can be used as an ideal adsorbent or a coating material used in various solid-phase extraction technologies, can also be used for preparation of molecularly imprinted sensors and chips, and has an important meaning for studying specific recognition and high-sensitivity detection on quinolone drugs.

The invention relates to a method for registration, identifying and processing of drug specific data and for making drugs available to individual patients without severe adverse drug reactions. The invention relates also to a system for carrying out such a method. According to the present invention, the system comprises a master database correlating patterns of gene expression and genetic polymorphisms with drug-induced i.e. drug-related adverse effects and drug structure. The system also comprises a predictive data-tool. In this tool the structural and genetic fingerprints predictive for adverse effects in individual patients due to treatment with a selected drug are stored. The method according the invention is characterized in that the master database being coupled to the database of the predictive data-tool in such a way that a user of the system can develop and carry out different screening approaches either to verify the sociability of drugs for a specific selected category of patients or to search a specific drug for a selected category of patients which do not have adverse drug reactions or to make risk-analyses.

The invention discloses a method for predicting drug residues in grass carp tissue with a physiological pharmacokinetic model. The method comprises steps as follows: A, collecting physiological dissection parameters of grass carps; B, obtaining drug specificity parameters of norfloxacin in bodies of the grass carps; C, establishing the five-chamber model by using acslXtreme software; D, evaluating the model. According to the method, the five-chamber physiological pharmacokinetic model is established, and residue elimination curves of the norfloxacin in muscles, livers and kidneys of the grass carps are fitted successfully and are identical with measured values. The method has the advantages of capability of saving the cost substantially, convenience in operation and the like and is applicable to prediction of common drug residues in the grass carps.

The invention relates to a preparation method of a magnetic microspheres-based levofloxacin surface imprinted material. The preparation process mainly comprises three steps: preparation of magnetic microspheres; coating of the magnetic microspheres with a molecularly imprinted material; and elution of template molecules. A synthetic method provided by the invention is simple. The prepared magnetic microspheres-based surface molecularly imprinted material has specific recognition function, high adsorption capacity and rapid adsorption ability of levofloxacin and has chiral resolution function of ofloxacin, has good magnetic response and high mechanical strength, can be used as an absorption filler or a coating material, also can be used in preparation of a molecular imprinting sensor and a chip, and is of great significance for researches on specific recognition, chiral resolution and highly sensitive detection of floxacin drugs.

The present invention relates to a preparation method of a magnetic carbon nano-tube surface molecular imprinting material having an imprinting carrier with a functional monomer effect and adopting an alternative template technology to avoid template leakage. The preparation method mainly comprises the following steps: preparing magnetic carbon nano-tubes, preparing vinyl-modified magnetic carbon nano-tubes, carrying out a surface molecular imprinting polymerization reaction, and eluting the template molecules. According to the present invention, the synthesis method is simple and is easy to perform, the prepared magnetic carbon nano-tube surface molecular imprinting material has characteristics of uniform active center, strong recognition specificity, excellent magnetic property, high mechanical strength, high absorption capacity, rapid binding kinetics and the like; and the preparation method can be used for ideal absorption agents or coating materials, and chromatogram separation fillers of various types of solid-phase extraction technologies, can further be used for preparation of molecular imprinting sensors and chips, and provides important significance for special quinolone drug recognition and high sensitivity detection research.

The invention aims to provide a method for preparing a rapid detection kit based on penicillin-binding protein PBP6 beta-lactam antibiotic receptor assay as well as a used detection method, aiming at solving the problem of sieve leakage in the process of detecting beta-lactam medicines in a traditional ELISA method. The invention discloses a method for preparing a detection kit based on penicillin-binding protein PBP6 beta-lactam antibiotic receptor assay as well as an indirect competitive receptor assay method for detecting the content of beta-lactam drugs in milk by adopting the detection kit based on penicillin-binding protein PBP6 beta-lactam antibiotic receptor assay. The methods have the beneficial effects that by utilizing the characteristic that the penicillin-binding protein 6 can be specifically bound to the beta-lactam drugs, the drugs can be specifically identified in a buffer liquid system or a sample matrix extracting solution and are not influenced by other antibiotics such as macrolides, quinolones and tetracyclines.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.

The present invention describes a novel system, drug delivery device, mobile App, drug specific drug dispensing algorithm, and method to improve medication safety and effectiveness via the utilization of drug specific algorithms to control drug dispensing, avoid drug mediated adverse events, ensure prescription persistence and promote prescription compliance on a cost-effective real-time basis.

The invention relates to the field of biopharmacy, and in particular relates to an osteoclast targeting delivery system based on a small nucleic acid medicine and a preparation method of the osteoclast targeting delivery system, used for regulating the functions of the osteoclasts. The osteoclast targeting delivery system comprises lipidosome, osteoclast targeting molecules and the small nucleic acid medicine used for regulating the functions of the osteoclasts. The delivery system carries out targeting aiming at the osteoclasts, thus having relatively strong specificity; the delivery system can prevent the small nucleic acid medicine from being degraded by the substance in the body, and also can specifically deliver the small nucleic acid medicine into target cells, and thus the functions of the osteoclasts can be regulated by the small nucleic acid medicine.

Drug delivery compositions for specific delivery of a drug to a tumor are described. These compositions include a core for sequestering the drug and a shell to which a ligand is attached for delivery of a drug to target cells. Since normal cells may also be targeted by the ligand, the compositions embed the ligand in the shell until the localized conditions surrounding the tumor cause the ligand to be displayed on the surface of the shell. One composition exhibits shrinkage of the shell at tumor pH, whereas another composition exhibits extension of the ligand at tumor pH. Still another composition causes the ligand to be exhibited at an elevated temperature.

The invention discloses a kit for detecting a tetracycline drug and a detection method therefor. The kit comprises a microporous reagent and a test paper. The microporous reagent contains freeze-dried colloidal gold-labeled tetracycline drug specific antibodies. The tetracycline drug specific antibodies are tetracycline drug monoclonal antibodies or tetracycline drug polyclonal antibodies. The test paper comprises a sample adsorption pad, a reaction film, a water adsorption pad, a protective film and a base plate, wherein the sample adsorption pad, the reaction film, the water adsorption pad, the protective film and the base plate are connected orderly. The reaction film comprises a detection zone and a quality control zone. The detection zone is coated with a tetracycline hapten-carrier protein conjugate. The quality control zone is coated with antiantibodies. The detection method suitable for the kit has simple processes, realizes fast, visual and accurate detection, has a wide application range and a low cost, and can be used and popularized easily.

The invention provides an enzyme linked immunosorbent assay kit for detecting nitroimidazole drugs. The kit comprises an enzyme labeling plate coated with metronidazole coupling antigen, enzyme labeling antiantibody working solution, specific antibody working solution of the nitroimidazole drugs, metronidazole standard substance solution, substrate developing solution, stop solution, concentrated washing solution and redissolving solution. The invention further discloses a method for detecting the nitroimidazole drugs by utilizing the enzyme linked immunosorbent assay kit. The method comprises the following steps of: firstly, carrying out sample preprocessing; secondly, carrying out detection by utilizing the kit; and thirdly, analyzing a detection result. The enzyme linked immunosorbent assay kit provided by the invention can be used for detecting the content of the nitroimidazole drugs in a honey sample, is simple and convenient to operate, is low in cost, can realize on-site monitoring and is suitable for screening of a large number of samples.

The invention discloses a chromatographic column decorated by lipid rafts. The chromatographic column is a silica gel chromatographic column which is decorated with the lipid rafts on the surface. A TrkA lipid raft-sillica gel stationary phase chromatographic system is built firstly. Stationary phase can be combined with medicinal specificity of tyrosine kinase receptors as a target spot, and then reservation is produced, but non-reservation behavior is not existed in the TrkA lipid raft-sillica gel chromatographic column of the tyrosine kinase target spot medicines. Lipid raft-sillica gel chromatograph which is rich in TrkA receptors is a novel medicine screening model which has a living being affiliation character and is capable of selective recognition medicines, wherein the medicines are reacted with the TrkA receptors. The chromatographic system is different from the traditional chromatographic system and has double characters of chromatograph separation and activity recognition. Therefore, the chromatographic system can be used for guide medicine screening study where the TrkA receptors served as drones. The chromatographic column decorated by the lipid rafts is used through different time and different moving phases, and the TrkA lipid raft-sillica gel stationary phase chromatographic system is proved stable. The chromatographic column is good in repeatability, long in service life and has good application prospects. The invention discloses a manufacturing method of the chromatographic column decorated by the lipid rafts.

An astrocyte-specific drug carrier containing a retinoid derivative and / or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

The invention discloses a kit and a method for detecting beta-lactam antibiotic and tetracycline antibiotic. The kit comprises micropore strips, micropore reagents, test paper and micropore plugs, wherein the micropore reagents are lyophilized colloidal gold labeled cephalosporins and tetracyclines specific antibodies, the cephalosporins specific antibodies comprise cephalosporins monoclonal antibodies and cephalosporins polyclonal antibodies, the tetracyclines specific antibodies comprise tetracyclines monoclonal antibodies and cephalosporins polyclonal antibodies; the test paper comprises a sample absorption pad, a reaction film, a water absorption pad, a protection film and a base plate which are connected in sequence, the reaction film comprises two detection lines and a quality control line, each detection lines comprises cephalosporins-carrier protein conjugates and tetracyclines hapten-carrier protein conjugates, and the quality control line comprises antiantibodies. According to the invention, the method for detecting beta-lactam antibiotic and tetracycline antibiotic by using the kit is simple, rapid, visual, accurate, portable, wide in application range, low in cost and easy to popularize.

With a biconcave disk-shaped red blood cell structure with hemoglobin, a natural cytomembrane and magnetic micro-nano particles as materials, by utilizing the chemical coprecipitation method and the cytomembrane fusion technique to integrate the main constituents of the red blood cell, i.e., the hemoglobin, the magnetic micro-nano particles and the cytomembrane with cellular biological properties,the invention prepares an artificial red blood cell motor with a biconcave disk-shaped red blood cell structure. Compared with the prior art, the invention has the following advantages: the repeatability of the invention is high, the preparation process is simple, and the prepared artificial motor has cell-like biological properties and good stability, and can quickly move along an acoustic pressure gradient under the drive of an exogenous ultrasonic field; moreover, the artificial red blood cell motor can also specifically identify cells (such as cancer cells) by means of the surface-modifying natural cytomembrane, or by applying an exogenous magnetic field, the targeting movement of the artificial red blood cell motor along a movement direction is realized, and the artificial red bloodcell motor has a broad application prospect in the biomedical field, such as oxygen target delivery, specific drug carrying, toxin removal and tumor treatment.

It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. This drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter.